COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT)

References

• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet Lond Engl. 2004 May;363(9422):1711–1720. doi: 10.1016/S0140-6736(04)16257-0
   PubMed Web of Science ®Google Scholar
• Stolz J, Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014 Sep;1967. doi: 10.2147/OPTH.S59162
   PubMedGoogle Scholar
• Aihara M, Adachi M, Matsuo H, et al. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Acta Ophthalmol. 2017 Dec;95(8):e720–e726. doi: 10.1111/aos.13401
   PubMed Web of Science ®Google Scholar
• Aref AA, Geyman LS, Zakieh A-R, et al. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension. Expert Rev Clin Pharmacol. 2019 Dec;12(12):1073–1079. doi: 10.1080/17512433.2019.1701435
   PubMed Web of Science ®Google Scholar
• Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012 Apr;13(5):723–745. doi: 10.1517/14656566.2012.662219
   PubMedGoogle Scholar
• Goldstein MH, Silva FQ, Blender N, et al. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022 Feb;36(2):361–368. doi: 10.1038/s41433-021-01668-x
   PubMed Web of Science ®Google Scholar
• Kestelyn PA, Kestelyn PG, De Bacquer D, et al. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. Int Ophthalmol. 2019 Jan;39(1):105–109. doi: 10.1007/s10792-017-0792-z
   PubMed Web of Science ®Google Scholar
• Walsh K, Jones L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019 Aug;13:1409–1425. doi: 10.2147/OPTH.S211611
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013 Dec;22(9):730–735. doi: 10.1097/IJG.0b013e31825af67d
   PubMed Web of Science ®Google Scholar
• Cha S-H, Lee J-S, Oum B-S, et al. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol. 2004 Apr;32(2):180–184. doi: 10.1111/j.1442-9071.2004.00782.x
   PubMed Web of Science ®Google Scholar
• De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619–630.
   PubMed Web of Science ®Google Scholar
• Misiuk-Hojlo M, Pomorska M, Mulak M, et al. The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol. 2019 Mar;29(2):210–215. doi: 10.1177/1120672118785280
   PubMed Web of Science ®Google Scholar
• Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017 Dec;5(12):e1221–e1234. doi: 10.1016/S2214-109X(17)30393-5
   PubMed Web of Science ®Google Scholar
• Aptel F, Pfeiffer N, Schmickler S, et al. Noninferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension:. J Glaucoma. 2019 Jun;28(6):498–506. doi: 10.1097/IJG.0000000000001248
   PubMed Web of Science ®Google Scholar
• Economou MA, Laukeland H, Grabska-Liberek I, et al. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clin Ophthalmol. 2018 Nov;12:2399–2407. doi: 10.2147/OPTH.S176605
   PubMed Web of Science ®Google Scholar
• El Ameen A, Vandermeer G, Khanna RK, et al. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2019 Nov;29(6):645–653. doi: 10.1177/1120672118805877
   PubMed Web of Science ®Google Scholar
• Markus C, Walimbe T, Chelerkar V, et al. Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma. Clin Ophthalmol. 2016 May 821. doi: 10.2147/OPTH.S102976
   PubMedGoogle Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2009 Mar;88(3):329–336. doi: 10.1111/j.1755-3768.2010.01907.x
   Web of Science ®Google Scholar
• Gordon MO. The ocular hypertension treatment study: design and Baseline description of the participants. Arch Ophthalmol. 1999 May;117(5):573. doi: 10.1001/archopht.117.5.573
   PubMed Web of Science ®Google Scholar
• Snow G, “Randomization for block random clinical trials.” Apr. 01, 2020.
   Google Scholar
• Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat. 2013;12(6):337–347. doi: 10.1002/pst.1549
   PubMed Web of Science ®Google Scholar
• Rouland J-F, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013 Feb;97(2):196–200. doi: 10.1136/bjophthalmol-2012-302121
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007 Jan;16(1):98–103. doi: 10.1097/01.ijg.0000212274.50229.c6
   PubMed Web of Science ®Google Scholar
• Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008 Apr;17(3):217–222. doi: 10.1097/IJG.0b013e31815a3472
   PubMed Web of Science ®Google Scholar
• Wong TT, Aung T, Ho CL. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride. Clin Experiment Ophthalmol. 2018 Dec;46(9):1028–1034. doi: 10.1111/ceo.13329
   PubMed Web of Science ®Google Scholar
• Baudouin C, Renard J-P, Nordmann J-P, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013 Jan;23(1):47–54. doi: 10.5301/ejo.5000181
   Web of Science ®Google Scholar
• Pisella PJ. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002 Apr;86(4):418–423. doi: 10.1136/bjo.86.4.418
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013 May;23(3):296–302. doi: 10.5301/ejo.5000220
   PubMed Web of Science ®Google Scholar
• Iester M, Telani S, Frezzotti P, et al. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014 Aug;30(6):476–481. doi: 10.1089/jop.2013.0216
   PubMed Web of Science ®Google Scholar
• Lopes NLV, Gracitelli CPB, Chalita MR, et al. Ocular surface evaluation after the substitution of benzalkonium chloride preserved prostaglandin eye drops by a preservative-free prostaglandin analogue. Med Hypothesis Discov Innov Ophthalmol J. 2019;8(1):52–56.
   PubMedGoogle Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007 May;17(3):341–349. doi: 10.1177/112067210701700311
   PubMed Web of Science ®Google Scholar
• Aguayo Bonniard A, Yeung JY, Chan CC, et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1279–1289. doi: 10.1080/17425255.2016.1209481
   PubMed Web of Science ®Google Scholar
• Angmo D, Wadhwani M, Velpandian T, et al. Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations. Int Ophthalmol. 2017 Apr;37(2):423–428. doi: 10.1007/s10792-016-0280-x
   PubMed Web of Science ®Google Scholar
• Golan S, Rosenfeld E, Shemesh G, et al. Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clin Exp Pharmacol Physiol. 2015 Feb;42(2):220–224. doi: 10.1111/1440-1681.12329
   PubMed Web of Science ®Google Scholar
• Narayanaswamy A, Neog A, Baskaran M, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan ® in comparison with generic latanoprost (latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55(2):127. doi: 10.4103/0301-4738.30707
   PubMedGoogle Scholar
• Diagourtas A, Kagelaris K, Oikonomakis K, et al. Prospective study comparing Xalatan ® eye drops and two similar generics as to the efficacy and safety profile. Eur J Ophthalmol. 2018 Jul;28(4):378–384. doi: 10.1177/1120672117747030
   PubMed Web of Science ®Google Scholar
• Digiuni M, Manni G, Vetrugno M, et al. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension:. J Glaucoma. 2013 Dec;22(9):707–712. doi: 10.1097/IJG.0b013e318259b47c
   PubMed Web of Science ®Google Scholar
• Brant Fernandes RA, Silva LMP, Dias DT, et al. Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial. Clin Ophthalmol. 2019 Apr;13:679–684. doi: 10.2147/OPTH.S198229
   PubMed Web of Science ®Google Scholar
• Diaconita V, Quinn M, Jamal D, et al. Washout duration of prostaglandin analogues: a systematic review and meta-analysis. J Ophthalmol. 2018 Sep;2018:1–8. doi: 10.1155/2018/3190684
   Web of Science ®Google Scholar